Group 1 | Group 2 | ||
---|---|---|---|
CRP at entry (mg/l) | CRP after 1 month (mg/l) | CRP at entry (mg/l) | CRP after 1 month (mg/l) |
Group 1 includes patients treated with irbesartan; group 2 includes patients treated with placebo on top of standard anti-ischaemic therapy. | |||
11.36 | 5.2 | 1.57 | 1.82 |
2.02 | 0.32 | 2.48 | 2.99 |
1.08 | 0.2 | 2.51 | 0.99 |
17.7 | 0.4 | 2.31 | 2.25 |
4.28 | 0.16 | 21.97 | 4.09 |
4.79 | 0.94 | 1.48 | 1.12 |
1.39 | 0.99 | 7.6 | 3.02 |
0.89 | 1.29 | 1.1 | 3.5 |
8.93 | 1.83 | 10.31 | 1.07 |
0.7 | 2.44 | 2.5 | 2.25 |
9.21 | 1.29 | 1.5 | 1.2 |
3.99 | 1.11 | 3.5 | 2.9 |
1.57 | 1.38 |